NYSE:RCUS 14 December 2025 - 8 January 2026

Arcus Biosciences, Inc. is ending the weekend under a bright—and volatile—spotlight after a major clinical-program reset triggered a sharp Friday selloff. As of Sunday, December 14, 2025, the last reported close was $21.53, down 14.36% from the prior session, reflecting investor repricing after Arcus and partner Gilead halted a pivotal upper-GI cancer study. StockAnalysis